SCHEMBL21434145

SCHEMBL21434145

FC(F)(F)Oc1ccc(-c2cc(N3CCCCC3)ncn2)cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMO O15229 7/20 0.57
▸ NPC1 O15118 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ RECQL P46063 1/20 0.52
▸ RAB9A P51151 1/20 0.52
▸ SMN1; SMN2 Q16637 1/20 0.52
▸ GRIN2B Q13224 6/20 0.41
▸ HRH4 Q9H3N8 1/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ DPP4 P27487 1/20 0.39
▸ SUV39H2 Q9H5I1 1/20 0.38
▸ PIK3CA P42336 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21434147 0.87 NPC1 (0.53) KMONPC1TSHRRECQLRAB9A
SCHEMBL21452773 0.86 KMO (0.50) KMONPC1TSHRRECQLRAB9A
SCHEMBL21452771 0.86 KMO (0.50) KMONPC1TSHRRECQLRAB9A
SCHEMBL21434116 0.86 NPC1 (0.52) KMONPC1TSHRRECQLRAB9A
SCHEMBL21434142 0.85 TSHR (0.51) KMONPC1TSHRRECQLRAB9A
SCHEMBL21433931 0.83 KMO (0.57) KMOKDM4E
SCHEMBL21434172 0.82 NPC1 (0.62) NPC1TSHRRECQLRAB9ASMN1; SMN2
SCHEMBL21434062 0.80 KMO (0.53) KMOSUV39H2
SCHEMBL14742275 0.79 KMO (0.68) KMOGRIN2B
SCHEMBL21434180 0.77 NPC1 (0.52) NPC1TSHRRECQLRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210340121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-11-04 — — US disclosed
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2021-05-18 — — US disclosed
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190308950-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3B KMO 1063/4885NPC1 3441/4885TSHR 1099/4885
US-20210340121-A1 SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN3B KMO 1063/4885NPC1 3441/4885TSHR 1099/4885
US-11008302-B2 Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators GRIN2B, GRIN2A, GRIN3B KMO 1078/4885NPC1 3519/4885TSHR 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback